Vitamin D regulates human ectocervical epithelial cell proliferation and insulin-like growth factor-binding protein-3 level

Biology of Reproduction

Volumn 60, Issue 3, 1999, Pages 567-572

  Agarwal, Chapla ^a   Lambert, Adam ^a   Chandraratna, Roshantha A S ^b   Rorke, Ellen A ^a   Eckert, Richard L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; ESTROGEN; GESTAGEN; RETINOID; SOMATOMEDIN BINDING PROTEIN 3; VITAMIN D;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VITAMIN METABOLISM;

EID: 0033034618     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod60.3.567     Document Type: Article

References (52)

1. Gorodeski GI, Eckert RL, Utian WH, Sheean L, Rorke EA. Retinoids, sex steroids and glucocorticoids regulate ectocervical cell envelope formation but not the level of the envelope precursor, involucrin. Differentiation 1989; 42:75-80.
2. Gorodeski GI, Eckert RL, Utian WH, Rorke EA. Maintenance of in vivo-like keratin expression, sex steroid responsiveness, and estrogen receptor expression in cultured human ectocervical epithelial cells. Endocrinology 1990; 126:399-406.
3. Sizemore N, Rorke EA. Human papillomavirus 16 immortalization of normal human ectocervical epithelial cells alters retinoic acid regulation of cell growth and epidermal growth factor receptor expression. Cancer Res 1993; 53:4511-4517.
4. Batova A, Danielpour D, Pirisi L, Creek KE. Retinoic acid induces secretion of latent transforming growth factor beta 1 and beta 2 in normal and human papillomavirus type 16-immortalized human keratinocytes. Cell Growth Differ 1992; 3:763-772.
5. Choo CK, Rorke EA, Eckert RL. Retinoid regulation of cell differentiation in a series of human papillomavirus type 16-immortalized human cervical epithelial cell lines. Carcinogenesis 1995; 16:375-381.
6. Agarwal C, Hembree JR, Rorke EA, Eckert RL. Interferon and retinoic acid suppress the growth of human papillomavirus type 16 immortalized cervical epithelial cells, but only interferon suppresses the level of the human papillomavirus transforming oncogenes. Cancer Res 1994; 54:2108-2112.
7. Eckert RL, Agarwal C, Hembree JR, Choo CK, Sizemore N, Andreatta Van Leyen S, Rorke EA. Human cervical cancer. Retinoids, interferon and human papillomavirus. Adv Exp Med Biol 1995; 375:31-44.
8. Gopinath R, Walton PE, Etherton TD. An acid-stable insulin-like growth factor (IGF)-binding protein from pig serum inhibits binding to IGF-I and IGF-II to vascular endothelial cells. J Endocrinol 1989; 120:231-236.
9. Conover CA, Ronk M, Lombana F, Powell DR. Structural and biological characterization of bovine insulin-like growth factor binding protein-3. Endocrinology 1990; 127:2795-2803.
10. Hembree JR, Agarwal C, Beard RL, Chandraratna RAS, Eckert RL. Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor-specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells. Cancer Res 1996; 56:1794-1799.
11. Andreatta Van Leyen S, Hembree JR, Eckert RL. Regulation of insulin-like growth factor 1 binding protein 3 levels by epidermal growth factor and retinoic acid in cervical epithelial cells. J Cell Physiol 1994; 160:265-274.
12. Hembree JR, Agarwal C, Eckert RL. Epidermal growth factor suppresses insulin-like growth factor binding protein 3 levels in human papillomavirus type 16-immortalized cervical epithelial cells and thereby potentiates the effects of insulin-like growth factor 1. Cancer Res 1994; 54:3160-3166.
13. Agarwal C, Chandraratna RAS, Teng M, Nagpal S, Rorke EA, Eckert RL. Differential regulation of human ectocervical epithelial cell line proliferation and differentiation by retinoid X receptor and retinoic acid receptor-specific retinoids. Cell Growth Differ 1996; 7:521-530.
14. Yu J, Papavasiliou V, Rhim J, Goltzman D, Kremer R. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs 1995; 6:101-108.
15. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994; 54:805-810.
16. Anzano MA, Smith JM, Uskokovic MR, Peer CW, Mullen LT, Letterio JJ, Welsh MC, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB. 1 alpha.25-Dihydroxy-16-ene-23-yne-26.27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994; 54:1653-1656.
17. Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT, Combes RC. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991; 337:701-702.
18. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 1995; 136:20-26.
19. James SY, Mackay AG, Colston KW. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol 1995; 14:391-394.
20. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10:142-153.
21. Kane KF, Langman MJ, Williams GR. Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid. Cancer Res 1996; 56:623-632.
22. Naveilhan P, Berger F, Haddad K, Barbot N, Benabid AL, Brachet P, Wion D. Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors? J Neurosci Res 1994; 37:271-277.
23. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding sutides. Anal Biochem 1986; 154:130-143.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 1970; 227:680-685.
25. Gilfix BM, Eckert RL. Coordinate control by vitamin A of keratin gene expression in human keratinocytes. J Biol Chem 1985; 260: 14026-14029.
26. Wood WI, Cachianes G, Henzel WJ, Winslow GA, Spencer SA, Hellmiss R, Martin JL, Baxter RC. Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein. Mol Endocrinol 1988; 2:1176-1185.
27. Tso JY, Sun XH, Kao TH, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res 1985; 13:2485-2502.
28. Su W, Jackson S, Tjian R, Echols H. DNA looping between sites for transcriptional activation: self-association of DNA-bound Sp1. Genes Dev 1991; 5:820-826.
29. Darwish HM, DeLuca HF. Recent advances in the molecular biology of vitamin D action. Prog Nucleic Acid Res Mol Biol 1996; 53:321-344.
30. Narvaez CJ, Vanweelden K, Byrne I, Welsh J. Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology 1996; 137:400-409.
31. Brenner RV, Shabahang M, Schumaker LM, Nauta RJ, Uskokovic MR, Evans SR, Buras RR. The antiproliferative effect of vitamin D analogs on MCF-7 human breast cancer cells. Cancer Lett 1995; 92: 77-82.
32. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 1994; 72:537-545.
33. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, Evans SR. Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 1994; 31:191-202.
34. James SY, Mackay AG, Binderup L, Colston KW. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol 1994; 141:555-563.
35. Allewaert K, Zhao XY, Zhao J, Glibert F, Branisteanu D, De Clercq P, Vandewalle M, Bouillon R. Biological evaluation of epoxy analogs of 1 alpha.25-dihydroxyvitamin D3. Steroids 1995; 60:324-332.
36. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 1994; 14:1077-1081.
37. Danielpour D. Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 1996; 166: 231-239.
38. Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Uskokovic MR, Brenner RV, Evans SR. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Cancer Res 1994; 54:4057-4064.
39. Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Evans SR. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993; 53:3712-3718.
40. Zhao X, Feldman D. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology 1993; 132:1808-1814.
41. Park K, Bae H, Heydemann A, Roberts AB, Dotto GP, Sporn MB, Kim SJ. The E1A oncogene induces resistance to the effects of 1,25-dihydroxyvitamin D3 on inhibition of growth of mouse keratinocytes. Cancer Res 1994; 54:6087-6089.
42. Agarwal C, Rorke EA, Irwin JC, Ecken RL. Immortalization by human papillomavirus type 16 alters retinoid regulation of human ectocervical epithelial cell differentiation. Cancer Res 1991; 51:3982-3989.
43. Byrne PM, Freaney R, McKenna MJ. Vitamin D supplementation in the elderly: review of safety and effectiveness of different regimes. Calcif Tissue Int 1995; 56:518-520.
44. Eckert RL, Agarwal C, Hembree JR, Choo CK, Sizemore N, Andreatta-van Leyen S, Rorke EA. Retinoids, interferon, human papillomavirus and cancer. In: Mukhtar H (ed.), Skin Cancer: Mechanisms and Human Relevance. Boca Raton. FL: CRC Press; 1995; 361-370.
45. Conover CA, Powell DR. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-1-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology 1991; 129: 710-716.
46. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, Bierich JR. Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. Endocrinology 1989; 125:766-772.
47. DeMellow JS, Baxter RC. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 1988; 156:199-204.
48. Ernst M, Rodan GA. Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology 1990; 127:807-814.
49. Yang YW, Yanagishita M, Rechler MM. Heparin inhibition of insulin-like growth factor-binding protein-3 binding to human fibroblasts and rat glioma cells: role of heparan sulfate proteoglycans. Endocrinology 1996; 137:4363-4371.
50. Conover CA, Clarkson JT, Bale LK. Factors regulating insulin-like growth factor-binding protein-3 binding, processing, and potentiation of insulin-like growth factor action. Endocrinology 1996; 137:2286-2292.
51. Conover CA, Bale LK, Clarkson JT, Durham SK. Potentiation of insulin-like growth factor action by insulin-like growth factor binding protein-3: studies of underlying mechanism. Growth Regul 1993; 3: 87-88.
52. Agarwal C, Chandraratna RAS, Johnson AT, Rorke EA, Eckert RL. AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. J Biol Chem 1996; 271:12209-12212.